GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Astellas Submits New Drug Application Targeting First ADC Approval for Metastatic Urothelial Cancer in Japan

by Tyler Chen
Share To

Urothelial cancer accounts for up to 90% of bladder cancers. Each year, 24,300 new cases and 200,000 deaths are reported in Japan. It is especially challenging for advanced and metastatic urothelial cancer patients because of the costly treatment and poor five-year survival rate, which is a mere 7%. What’s worse, patients who progressed after chemotherapy or immunotherapy don’t have a standard treatment.

 

Targeting First Japanese Approval for ADC in Urothelial Cancer

Astellas Pharma has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication.

Enfortumab vedotin is an antibody-drug conjugate (ADC) that targets a highly expressed protein in bladder cancer called Nectin-4. It can bind to Nectin-4 and release anti-tumor agent monomethyl auristatin E (MMAE) to stop the cell from reproduction and begin apoptosis.

It should be noted that if the drug is approved, it will be the first ADC approved for the indication in Japan.

 

Meeting Primary Endpoints in Two Clinical Trials

The NDA comes after enfortumab vedotin met the primary endpoints in two clinical trials conducted in Japan.

In Phase 2 clinical trial EV-201 (NCT03219333), enfortumab vedotin was examined with 2 groups of patients: those who have also been treated with platinum-containing chemotherapy and those who have not received platinum-containing chemotherapy and who are ineligible for cisplatin. The primary endpoint is the ORR per blinded independent central review.

In Phase 3 clinical trial EV-301 (NCT03474107), enfortumab vedotin was evaluated with about 600 patients with locally advanced or metastatic urothelial cancer who were previously treated with a PD-1 or PD-L1 inhibitor and platinum-based therapies. It is compared to the control group that took physician’s choice of chemotherapy like docetaxel, paclitaxel, or vinflunine.

After 11 months of follow-up, enfortumab vedotin showed better median OS (3.9 months), progression-free survival (5.6 months), ORR (40.6%), and DCR (71.9%) than chemotherapy.

Andrew Krivoshik, M.D., Ph.D., Senior Vice President, and Oncology Therapeutic Area Head, Astellas said, “Based on data from two global clinical trials, and following the Ministry of Health, Labour and Welfare’s review, enfortumab vedotin may offer a new option for these patients.”

Related Articles: Bavencio Bags FDA Approval as First-line Maintenance Treatment for Urothelial Carcinoma

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top